…
Predictive Oncology Inc., a knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of optimal cancer therapies. It operates through three segments: Pittsburgh, Birmingham, and Eagan. The Pittsburgh segment provides services that include the application of AI using its proprietary biobank of approximately 150,000 tumor samples and creates proprietary 3D culture models used in drug development. The Birmingham segment offers contract services and research focused on solubility improvements, stability studies, and protein production. The Eagan segment produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Pittsburgh, Pennsylvania.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -25.74M | -20.32M | -25.88M | -19.39M | -10.09M |
| Net income | -36.21M | -19.66M | -37.70M | -27.56M | -10.09M |
| Selling general administrative | 11.11M | 10.93M | 10.35M | 9.78M | 4.63M |
| Selling and marketing expenses | 1.36M | 0.77M | 0.58M | 1.91M | 2.37M |
| Gross profit | 1.00M | 0.93M | 0.81M | 0.88M | 1.00M |
| Reconciled depreciation | 1.31M | 1.34M | 1.02M | 0.70M | 0.15M |
| Ebit | -15.27M | -13.47M | -0.67M | -13.77M | -7.86M |
| Ebitda | -3.30M | -6.68M | 0.36M | -4.90M | -7.71M |
| Depreciation and amortization | 11.96M | 6.79M | 1.02M | 8.87M | 0.15M |
| Non operating income net other | - | - | -1.81M | - | - |
| Operating income | -15.27M | -13.47M | -0.67M | -13.77M | -7.86M |
| Other operating expenses | 16.77M | 14.89M | 13.74M | 15.19M | 9.27M |
| Interest expense | 10.65M | 12.30M | 0.00M | 0.00M | 0.00M |
| Tax provision | 0.00M | -0.66M | - | - | - |
| Interest income | - | - | - | 5.72M | 2.29M |
| Non recurring | - | - | 12.88M | - | - |
| Income tax expense | 10.47M | -0.66M | 11.82M | 8.17M | -2.23M |
| Total revenue | 1.51M | 1.42M | 1.25M | 1.41M | 1.41M |
| Total operating expenses | 16.27M | 14.41M | 13.29M | 14.65M | 8.86M |
| Cost of revenue | 0.51M | 0.49M | 0.45M | 0.53M | 0.42M |
| Total other income expense net | -10.47M | -6.85M | -25.22M | -5.62M | -2.23M |
| Net income from continuing ops | -25.74M | -19.66M | -25.88M | -19.39M | -10.09M |
| Net income applicable to common shares | -25.74M | -19.66M | -26.44M | -19.68M | -10.09M |
| Preferred stock and other adjustments | - | - | 0.55M | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 14.42M | 25.73M | 43.77M | 13.06M | 22.38M |
| Intangible assets | 0.25M | 0.25M | 3.96M | 3.40M | 3.65M |
| Other current assets | 0.52M | 0.53M | 0.51M | 0.29M | 0.16M |
| Total liab | 6.15M | 3.97M | 3.51M | 10.42M | 11.14M |
| Total stockholder equity | 8.27M | 21.77M | 40.27M | 2.64M | 11.23M |
| Other current liab | 1.63M | 2.24M | 1.39M | 2.88M | 2.42M |
| Common stock | 0.04M | 0.79M | 0.66M | 0.20M | 0.04M |
| Capital stock | 0.04M | 0.79M | 0.66M | 0.20M | 0.08M |
| Retained earnings | -167.76M | -153.78M | -128.04M | -108.38M | -82.50M |
| Other liab | - | - | 0.03M | 0.24M | - |
| Good will | - | 0.00M | 6.86M | 2.81M | 15.69M |
| Other assets | - | 0.08M | 0.17M | 1.51M | - |
| Cash | 8.73M | 22.07M | 28.20M | 0.68M | 0.15M |
| Total current liabilities | 3.95M | 3.88M | 3.24M | 9.34M | 10.87M |
| Current deferred revenue | 0.31M | 0.60M | 0.19M | 0.05M | 0.04M |
| Net debt | -5.87M | -21.89M | -27.32M | 5.20M | 5.37M |
| Short term debt | 0.67M | 0.09M | 0.64M | 5.03M | 5.26M |
| Short long term debt | 0.15M | - | - | 4.43M | 4.80M |
| Short long term debt total | 2.86M | 0.18M | 0.88M | 5.87M | 5.53M |
| Other stockholder equity | 175.99M | 174.76M | 167.65M | 110.83M | 93.65M |
| Property plant equipment | - | 2.05M | 3.33M | 5.22M | 2.24M |
| Total current assets | 10.08M | 23.36M | 29.46M | 1.51M | 0.80M |
| Net tangible assets | - | 21.51M | 29.44M | -3.57M | -8.14M |
| Net receivables | 0.33M | 0.33M | 0.35M | 0.26M | 0.30M |
| Inventory | 0.49M | 0.43M | 0.39M | 0.29M | 0.19M |
| Accounts payable | 1.34M | 0.94M | 1.02M | 1.37M | 3.16M |
| Accumulated other comprehensive income | -0.00M | - | - | - | -0.77M |
| Common stock total equity | - | - | - | 0.20M | 0.04M |
| Preferred stock total equity | - | - | - | 0.00M | - |
| Retained earnings total equity | - | - | - | -108.38M | - |
| Non currrent assets other | 0.13M | 0.08M | 0.17M | 0.12M | 21.58M |
| Non current assets total | 4.34M | 2.37M | 14.31M | 11.55M | 21.58M |
| Capital lease obligations | 2.71M | 0.18M | 0.88M | 1.44M | 0.73M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.48M | -10.61M | -0.17M | -0.60M | -1.11M |
| Change to liabilities | -0.04M | -0.30M | -1.64M | 0.38M | 0.32M |
| Total cashflows from investing activities | -0.48M | -10.61M | -0.17M | -0.60M | -1.11M |
| Net borrowings | - | -4.16M | 1.29M | 1.54M | 2.19M |
| Total cash from financing activities | 6.72M | 50.34M | 12.95M | 9.32M | 5.79M |
| Change to operating activities | 0.92M | -0.78M | 0.46M | 1.26M | 0.63M |
| Net income | -25.74M | -19.66M | -25.88M | -19.39M | -10.09M |
| Change in cash | -6.13M | 27.52M | 0.53M | -0.01M | -0.60M |
| Begin period cash flow | 28.20M | 0.68M | 0.15M | 0.16M | 0.77M |
| End period cash flow | 22.07M | 28.20M | 0.68M | 0.15M | 0.16M |
| Total cash from operating activities | -12.37M | -12.21M | -12.26M | -8.73M | -5.29M |
| Issuance of capital stock | 6.74M | 51.20M | 9.95M | 7.98M | 2.96M |
| Depreciation | 1.31M | 1.34M | 1.02M | 0.70M | 0.15M |
| Other cashflows from investing activities | - | - | 0.13M | -0.82M | -1.12M |
| Dividends paid | - | 4.51M | 2962.77M | - | - |
| Change to inventory | -0.04M | -0.10M | -0.09M | 0.09M | 0.02M |
| Change to account receivables | 0.02M | -0.02M | 0.07M | 0.14M | -0.10M |
| Sale purchase of stock | -0.03M | -0.01M | 2962.77M | 7.99M | 3.61M |
| Other cashflows from financing activities | -0.48M | 7.83M | 4.48M | 4.83M | 2.84M |
| Change to netincome | 11.19M | 7.06M | 12.57M | 6.06M | 3.38M |
| Capital expenditures | 0.48M | 0.96M | 0.36M | 0.03M | 0.23M |
| Change receivables | - | - | 0.07M | - | - |
| Cash flows other operating | - | - | 0.92M | - | - |
| Cash and cash equivalents changes | - | - | 0.53M | - | - |
| Change in working capital | 0.87M | -1.19M | -1.21M | 1.87M | 0.88M |
| Stock based compensation | - | 6.80M | - | - | - |
| Other non cash items | 11.19M | 1.17M | 13.81M | 8.08M | 3.77M |
| Free cash flow | -12.85M | -13.17M | -12.62M | -8.76M | -5.52M |
Sector: Healthcare Industry: Medical Instruments & Supplies
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| POAI Predictive Oncology Inc |
1.38 25.18% |
6.86 | - | - | 4.02 | 0.86 | 0.72 | -0.10 |
| ISRG Intuitive Surgical Inc |
3.70 0.84% |
443.59 | 43.30 | 31.35 | 12.25 | 7.35 | 11.63 | 30.22 |
| ESLOF EssilorLuxottica Société anonyme |
-8.90 4.32% |
197.19 | 44.84 | 27.62 | 4.07 | 2.49 | 3.71 | 16.04 |
| ESLOY Essilor International SA |
1.64 1.66% |
100.55 | 41.68 | 27.25 | 3.94 | 2.45 | 3.71 | 16.04 |
| BDX Becton Dickinson and Company |
2.32 1.08% |
218.03 | 31.62 | 13.76 | 2.25 | 2.04 | 2.93 | 13.40 |
Predictive Oncology Inc., a knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of optimal cancer therapies. It operates through three segments: Pittsburgh, Birmingham, and Eagan. The Pittsburgh segment provides services that include the application of AI using its proprietary biobank of approximately 150,000 tumor samples and creates proprietary 3D culture models used in drug development. The Birmingham segment offers contract services and research focused on solubility improvements, stability studies, and protein production. The Eagan segment produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Pittsburgh, Pennsylvania.
2915 Commers Drive, Eagan, MN, United States, 55121
651 389 4800
34
| Name | Title | Year Born |
|---|---|---|
| Mr. Raymond F. Vennare | CEO & Chairman | 1952 |
| Mr. Robert L. Myers M.B.A. | CFO & Sec. | 1955 |
| Mr. Richard L. Gabriel B.S., B.Sc, M.B.A., MBA | Sr. VP of R&D | 1949 |
| Dr. Julia Kirshner Ph.D. | Chief Scientific Officer | NA |
| Ms. Theresa Ferguson | Sr. Director of Marketing | NA |
| Ms. Pamela Bush M.B.A., Ph.D. | Sr. VP of Strategic Sales & Bus. Devel. | NA |
| Dr. Lawrence J. DeLucas D.Sc, O.D, Ph.D. | Sr. VP of Protein Science | NA |
| Dr. Arlette H. Uihlein FCAP, M.D. | Sr. VP of Drug Discovery Operations & Medical Director | NA |
| Mr. Raymond F. Vennare | CEO & Chairman | 1953 |
| Mr. Joshua Blacher M.B.A. | Interim Chief Financial Officer | 1973 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.